CY1119115T1 - Πολυμερικα συζευγματα δραστικων αρχων, η διαδικασια παρασκευης τους και οι πολυμερικες ενδιαμεσες ενωσεις τους - Google Patents
Πολυμερικα συζευγματα δραστικων αρχων, η διαδικασια παρασκευης τους και οι πολυμερικες ενδιαμεσες ενωσεις τουςInfo
- Publication number
- CY1119115T1 CY1119115T1 CY20171100570T CY171100570T CY1119115T1 CY 1119115 T1 CY1119115 T1 CY 1119115T1 CY 20171100570 T CY20171100570 T CY 20171100570T CY 171100570 T CY171100570 T CY 171100570T CY 1119115 T1 CY1119115 T1 CY 1119115T1
- Authority
- CY
- Cyprus
- Prior art keywords
- polymeric
- polymeral
- unions
- procedure
- changes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
- C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
- C08G65/3328—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polyesters Or Polycarbonates (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Peptides Or Proteins (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται σε καινοτόμα συζεύγματα των δραστικών αρχών εμβολιασμένα σ' ένα πολυμερές, στα νανοσωματίδια που τα περιέχουν, την παρασκευή τους και στις πολυμερικές ενδιάμεσες ενώσεις.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1059561A FR2967581B1 (fr) | 2010-11-19 | 2010-11-19 | Conjugues polymeriques de principes actifs, leur procede de preparation et leurs intermediaires polymeriques |
PCT/EP2011/070441 WO2012066117A1 (en) | 2010-11-19 | 2011-11-18 | Polymeric conjugates of active principles, their process of preparation and their polymeric intermediates |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1119115T1 true CY1119115T1 (el) | 2018-02-14 |
Family
ID=43654132
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171100570T CY1119115T1 (el) | 2010-11-19 | 2017-05-31 | Πολυμερικα συζευγματα δραστικων αρχων, η διαδικασια παρασκευης τους και οι πολυμερικες ενδιαμεσες ενωσεις τους |
Country Status (18)
Country | Link |
---|---|
US (1) | US9278137B2 (el) |
EP (1) | EP2640422B1 (el) |
JP (2) | JP6013354B2 (el) |
AR (1) | AR084728A1 (el) |
CY (1) | CY1119115T1 (el) |
DK (1) | DK2640422T3 (el) |
ES (1) | ES2625173T3 (el) |
FR (1) | FR2967581B1 (el) |
HR (1) | HRP20170691T1 (el) |
HU (1) | HUE032590T2 (el) |
LT (1) | LT2640422T (el) |
PL (1) | PL2640422T3 (el) |
PT (1) | PT2640422T (el) |
RS (1) | RS56021B1 (el) |
SI (1) | SI2640422T1 (el) |
TW (1) | TW201302225A (el) |
UY (1) | UY33741A (el) |
WO (1) | WO2012066117A1 (el) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014015422A1 (en) * | 2012-07-27 | 2014-01-30 | Ontario Institute For Cancer Research | Cellulose-based nanoparticles for drug delivery |
JP6118914B2 (ja) * | 2012-12-28 | 2017-04-19 | ターベダ セラピューティクス インコーポレイテッドTarveda Therapeutics,Inc. | 放出制御型の固体ポリマーナノ粒子 |
ME02860B (me) | 2013-09-16 | 2018-04-20 | Astrazeneca Ab | Terapeutske polimerne nanočestice i postupci njihove pripreme i primene |
US10548881B2 (en) | 2016-02-23 | 2020-02-04 | Tarveda Therapeutics, Inc. | HSP90 targeted conjugates and particles and formulations thereof |
EP3823961A4 (en) * | 2018-07-19 | 2022-06-08 | Starpharma Pty Limited | THERAPEUTIC DENDRIMER |
CN110974972B (zh) * | 2019-12-03 | 2023-01-20 | 沈阳药科大学 | 难溶性药物的弱酸性衍生物及其脂质体制剂 |
CN113933441A (zh) * | 2021-09-30 | 2022-01-14 | 无锡紫杉药业有限公司 | 一种卡巴他赛及其中间体的测定方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5766635A (en) | 1991-06-28 | 1998-06-16 | Rhone-Poulenc Rorer S.A. | Process for preparing nanoparticles |
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
CZ2006207A3 (cs) * | 2006-03-28 | 2008-01-16 | Zentiva, A. S. | Micelární nosiče léčiv s protinádorovou aktivitou |
CN101701068B (zh) * | 2009-10-30 | 2011-09-21 | 北京化工大学 | 一种pH响应性的Y型药物输送材料及其制备方法 |
WO2011119995A2 (en) * | 2010-03-26 | 2011-09-29 | Cerulean Pharma Inc. | Formulations and methods of use |
CN103408710B (zh) * | 2013-06-19 | 2015-12-23 | 北京化工大学 | 一种生物可降解及糖响应性的y型高分子药物输送材料及制备 |
-
2010
- 2010-11-19 FR FR1059561A patent/FR2967581B1/fr active Active
-
2011
- 2011-11-18 LT LTEP11784668.3T patent/LT2640422T/lt unknown
- 2011-11-18 SI SI201131184T patent/SI2640422T1/sl unknown
- 2011-11-18 PT PT117846683T patent/PT2640422T/pt unknown
- 2011-11-18 TW TW100142380A patent/TW201302225A/zh unknown
- 2011-11-18 HU HUE11784668A patent/HUE032590T2/en unknown
- 2011-11-18 WO PCT/EP2011/070441 patent/WO2012066117A1/en active Application Filing
- 2011-11-18 ES ES11784668.3T patent/ES2625173T3/es active Active
- 2011-11-18 JP JP2013539283A patent/JP6013354B2/ja active Active
- 2011-11-18 PL PL11784668T patent/PL2640422T3/pl unknown
- 2011-11-18 US US13/877,757 patent/US9278137B2/en active Active
- 2011-11-18 RS RS20170450A patent/RS56021B1/sr unknown
- 2011-11-18 EP EP11784668.3A patent/EP2640422B1/en active Active
- 2011-11-18 AR ARP110104306A patent/AR084728A1/es not_active Application Discontinuation
- 2011-11-18 UY UY0001033741A patent/UY33741A/es not_active Application Discontinuation
- 2011-11-18 DK DK11784668.3T patent/DK2640422T3/en active
-
2016
- 2016-04-13 JP JP2016080318A patent/JP6165920B2/ja active Active
-
2017
- 2017-05-10 HR HRP20170691TT patent/HRP20170691T1/hr unknown
- 2017-05-31 CY CY20171100570T patent/CY1119115T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
FR2967581A1 (fr) | 2012-05-25 |
LT2640422T (lt) | 2017-06-26 |
PT2640422T (pt) | 2017-05-23 |
HRP20170691T1 (hr) | 2018-05-18 |
HUE032590T2 (en) | 2017-10-30 |
RS56021B1 (sr) | 2017-09-29 |
WO2012066117A1 (en) | 2012-05-24 |
FR2967581B1 (fr) | 2012-12-28 |
DK2640422T3 (en) | 2017-05-22 |
JP2013542972A (ja) | 2013-11-28 |
SI2640422T1 (sl) | 2017-10-30 |
US9278137B2 (en) | 2016-03-08 |
EP2640422A1 (en) | 2013-09-25 |
AR084728A1 (es) | 2013-06-05 |
US20130243719A1 (en) | 2013-09-19 |
EP2640422B1 (en) | 2017-03-01 |
ES2625173T3 (es) | 2017-07-18 |
JP6013354B2 (ja) | 2016-10-25 |
UY33741A (es) | 2012-03-30 |
JP6165920B2 (ja) | 2017-07-19 |
TW201302225A (zh) | 2013-01-16 |
PL2640422T3 (pl) | 2017-09-29 |
JP2016172858A (ja) | 2016-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1119115T1 (el) | Πολυμερικα συζευγματα δραστικων αρχων, η διαδικασια παρασκευης τους και οι πολυμερικες ενδιαμεσες ενωσεις τους | |
CY1120413T1 (el) | Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου | |
CY1123958T1 (el) | Μεθοδος παρασκευης παραγωγων και ενδιαμεσων καρβαμοϋλπυριδονης | |
CY1121862T1 (el) | Αντισωματα anti-phf-tau και χρησεις αυτων | |
CY1122824T1 (el) | Πρωτεϊνες συντηξης και εμβολια συνδυασμου | |
EA201200617A1 (ru) | Полимеры на основе циклодекстрина для доставки лекарственных средств | |
CY1117563T1 (el) | Αντισωματα κατα her3 και χρησεις αυτων | |
CY1119173T1 (el) | Νεα μορια αναστολεα jnk | |
BR112015027322A2 (pt) | compostos antissenso conjugados e sua utilização | |
CY1116192T1 (el) | Πυρρολοβενζοδιαζεπινες και συζευγματα αυτων | |
UA111818C2 (uk) | Антитіло проти csf-1r | |
MX336682B (es) | Anticuerpos contra csf-1r humanos y usos de los mismos. | |
EA201200122A1 (ru) | КОНЬЮГАТЫ ε-ПОЛИЛИЗИНА И ИХ ПРИМЕНЕНИЕ | |
EA201290838A1 (ru) | Конъюгаты пирролбензодиазепина направленного действия | |
EA201290072A1 (ru) | Полимерные частицы и их применение | |
BR112014005935A2 (pt) | derivados de anilina, sua preparação e sua aplicação terapêutica | |
AU2012228355A8 (en) | N-(1,2,5-oxadiazol-3-yl)-, N-(tetrazol-5-yl)- and N-(triazol-5-yl)bicycloarylcarboxamides and their use as herbicides | |
CY1122115T1 (el) | Παραγωγα ν1-ακυλο-5-φθοροπυριμιδινονης | |
EA201190283A1 (ru) | Мультивалентный адъювантный дисплей | |
CY1122711T1 (el) | Μεθοδος για την ενεργοποιηση και τη συζευξη βιομοριων | |
EA201290642A1 (ru) | Соединения и способы | |
CY1117249T1 (el) | Ενωσεις ως διαμορφωτες μιας μεταλλαγμενης πρωτεϊνης cftr και χρησης αυτων για την θεραπεια νοσων που συνδεονται με δυσλειτουργια της πρωτεϊνης cftr | |
CY1114880T1 (el) | Αγωνιστες mglu2 | |
EA201300132A1 (ru) | Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич | |
CY1119959T1 (el) | ΔΕΝΔΡΙΤΙΚΑ ΚΥΤΤΑΡΑ ΥΠΟΒΛΗΘΕΝΤΑ ΣΕ ΧΕΙΡΙΣΜΟ ΣΤΗΝ ΠΟΡΕΙΑ ΣΗΜΑΤΟΔΟΤΗΣΗΣ NFkB |